share_log

Angion Biomedica analyst ratings

Benzinga Analyst Ratings ·  Jun 30, 2022 06:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
06/30/2022 Oppenheimer Downgrades Outperform → Perform
06/30/2022 -12.28% Stifel $5 → $1.5 Downgrades Buy → Hold
05/23/2022 1537.43% HC Wainwright & Co. $32 → $28 Maintains Buy
04/18/2022 1771.35% HC Wainwright & Co. $50 → $32 Maintains Buy
12/10/2021 367.84% Oppenheimer $15 → $8 Maintains Outperform
11/09/2021 2823.98% HC Wainwright & Co. $100 → $50 Maintains Buy
10/27/2021 777.19% Stifel $40 → $15 Maintains Buy
03/02/2021 Cowen & Co. Initiates Coverage On → Outperform
03/02/2021 2122.22% Oppenheimer → $38 Initiates Coverage On → Outperform
03/02/2021 2239.18% Stifel → $40 Initiates Coverage On → Buy
03/01/2021 5747.95% HC Wainwright & Co. → $100 Initiates Coverage On → Buy

Angion Biomedica Questions & Answers

What is the target price for Angion Biomedica (ANGN)?

The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by Oppenheimer on June 30, 2022. The analyst firm set a price target for $0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Angion Biomedica (ANGN)?

The latest analyst rating for Angion Biomedica (NASDAQ: ANGN) was provided by Oppenheimer, and Angion Biomedica downgraded their perform rating.

When is the next analyst rating going to be posted or updated for Angion Biomedica (ANGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Angion Biomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Angion Biomedica was filed on June 30, 2022 so you should expect the next rating to be made available sometime around June 30, 2023.

Is the Analyst Rating Angion Biomedica (ANGN) correct?

While ratings are subjective and will change, the latest Angion Biomedica (ANGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Angion Biomedica (ANGN) is trading at is $1.71, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment